Zhejiang Kangyuan Medical Devices Acquired by TaiLin Pharmaceuticals — Healthcare M&A

TaiLin Pharmaceuticals (01011) has completed its acquisition of a controlling 58.11% equity stake in Zhejiang Kangyuan Medical Devices. The deal was structured as an add-on investment and is reported to be under $10m in value. To fund the consideration, TaiLin issued and allotted 275 million new shares at an issue price of HK$0.45 per share to eight sellers, completing payment following satisfaction of the transaction’s conditions precedent.

Zhejiang Kangyuan Medical Devices operates in China’s medical devices sector, aligning with TaiLin’s healthcare focus and expanding its exposure to device-related products and capabilities. The acquisition also results in the target becoming an indirect wholly-owned subsidiary through the transfer and registration of the issued share capital of the related entities involved in the transaction, supporting consolidation under TaiLin’s corporate structure.

With the equity transfer and registration completed, the transaction is now closed. The company’s share issuance and the fulfillment of the sale and purchase agreement requirements mark the final steps of the announced timetable, positioning TaiLin to integrate Zhejiang Kangyuan Medical Devices into its broader strategic platform in the medical devices market.